HC Wainwright & Co. Reiterates Buy on Decibel Therapeutics, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Decibel Therapeutics (NASDAQ:DBTX) and maintains a $23 price target.
June 06, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Decibel Therapeutics (DBTX) receives a reiterated Buy rating from HC Wainwright & Co. analyst Joseph Pantginis, with a maintained $23 price target.
The news of HC Wainwright & Co. analyst Joseph Pantginis reiterating a Buy rating on Decibel Therapeutics (DBTX) and maintaining a $23 price target is positive for the stock. This reaffirmation from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100